Erratum: Will PI3K pathway inhibitors be effective as single agents in patients with cancer?

Joan T. Garrett; Anindita Chakrabarty; Carlos L. Arteaga

doi:10.18632/oncotarget.26017

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Errata:

Erratum: Will PI3K pathway inhibitors be effective as single agents in patients with cancer?

PDF | How to cite

Oncotarget. 2018; 9:32400-32400. https://doi.org/10.18632/oncotarget.26017

Metrics: PDF 1255 views | ?

Joan T. Garrett¹, Anindita Chakrabarty¹ and Carlos L. Arteaga^1,2,3

¹ Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, TN, USA
² Department of Cancer Biology, Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, TN, USA
³ Breast Cancer Research Program, Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, TN, USA

Published: August 17, 2018

This article has been corrected: During production, the text of the subsections ‘INHIBITION OF P13K IS INCOMPLETE WITH SINGLE AGENTS’ and ‘CLINICAL IMPLICATIONS’ was duplicated within the article. The corrected version now has the duplicated text removed while preserving the original pagination.

Original article: Oncotarget. 2011; 2:1314-1321. DOI: https://doi.org/10.18632/oncotarget.409.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 26017

Publication Alerts

Errata:

Erratum: Will PI3K pathway inhibitors be effective as single agents in patients with cancer?